The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Nivolumab Superior to Ipilimumab as Adjuvant Therapy for Stage III/IV Resected Melanoma
Nivolumab (Opdivo) may represent a new standard option for adjuvant therapy for patients with resected stage IIIB/C and IV melanoma, whether or not they have a BRAF mutation. In a comparison with current standard high-dose ipilimumab (Yervoy), nivolumab demonstrated a significant improvement in relapse-free survival.
Dr. Hamid on Epacadostat Plus Pembrolizumab in Advanced Melanoma
September 11th 2017Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase III results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.
FDA Grants Cemiplimab Breakthrough Designation for CSCC
The FDA has granted a breakthrough therapy designation to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC.
Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer
September 8th 2017David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, discusses PD-L1 as a biomarker in lung cancer.
FDA Grants LN-144 Fast Track Status for Melanoma
The FDA has granted LN-144, an adoptive cell therapy that uses tumor-infiltrating lymphocyte technology developed by Iovance Biotherapeutics, a fast track designation for the treatment of patients with advanced melanoma.
Dr. Wilson on Choosing Between BRAF/MEK Therapies for Patients With Melanoma
August 16th 2017Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses how physicians select between the 2 BRAF/MEK inhibitor combination regimens for their patients with melanoma.
RT Options Evolving in Oligometastatic Lung Cancer Landscape and Beyond
August 14th 2017Billy W. Loo Jr, MD, PhD, discusses the advancements in radiation therapy options for patients with lung cancer, how SABR has improved outcomes for patients, and the intriguing combinations being explored with RT and immunotherapy.
Dr. Meehan on Importance of IHC Testing in Melanoma
July 31st 2017Shane A. Meehan, MD, associate professor, Ronald O. Perelman Department of Dermatology, associate professor, Department of Pathology, director of the Dermatopathology Fellowship Training Program, and director of the Dermatopathology Section at New York University Langone Medical Center, discusses the importance of immunohistochemistry (IHC) testing in melanoma.
Dr. Pavlick on Adjuvant Immunotherapy in High-risk Melanoma
July 27th 2017Anna C. Pavlick, DO, associate professor of hematology and medical oncology and medical director of the Clinical Trials Office at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the need for adjuvant immunotherapy in patients with high-risk melanoma.
Dr. Wilson on Long-term Data With Dabrafenib Plus Trametinib in Melanoma
July 27th 2017Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses the long-term data with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF-mutant melanoma.